2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma作者机构：Department of HematologyShanghai Tongji HospitalTongji University School of MedicineShanghai 200065China Department of Bio-therapeuticChinese PLA General HospitalBeijing 100853China Department of HematologyThe Second Affiliated HospitalCollege of MedicineZhejiang UniversityHangzhou 310009China Department of HematologyChinese PLA General HospitalBeijing 100853China Department of HematologyThe First Hospital of Jilin UniversityChangchun 130012China Center for Bone Marrow TransplantationThe First Affiliated HospitalSchool of MedicineZhejiang UniversityHangzhou 310058China Institute of HematologyUnion Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430022China Peking University People’s Hospital&Peking University Institute of HematologyBeijing Key Laboratory of Hematopoietic Stem Cell TransplantationBeijing 100044China Department of HematologyLymphoma Research CenterPeking University Third HospitalBeijing 100191China Department of HematologyThe First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjing 210029China Department of HematologyZhujiang HospitalSouthern Medical UniversityGuangzhou 510280China Department of HematologyNanfang HospitalSouthern Medical UniversityGuangzhou 510515China Lu Daopei Institute of HematologyBeijing 101102China Department of HematologyWest China HospitalSichuan UniversityChengdu 610041China The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou 450008China Department of LymphomaKey Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing)Peking University Cancer Hospital and InstituteBeijing 100142China Department of HematologyShanxi Cancer HospitalTaiyuan 030013China State Key Laboratory of Experimental HematologyNational Clinical Research Center for Blood DiseasesDivision of Pediatric Blood Disease CenterInstitute of Hematology&Blood Disease HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin 300020China Department of HematologyThe First Affiliated Hospital of Soochow UniversityJiangsu Institute of HematologyNational Clinical Research Center for Hematologic DiseasesSuzhou 215006China Department of HematologyBeijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of HematologyThe Affiliated Hospital of Xuzhou Medical UniversityXuzhou 221006China Institute of Blood and Marrow TransplantationThe Fifth Medical CenterChinese PLA General HospitalBeijing 100039China Department of LymphomaTianjin Medical University Cancer Institute&HospitalNational Clinical Research Center for CancerKey Laboratory of Cancer Prevention and TherapyTianjinTianjin’s Clinical Research Center for CancerTianjin 300060China Medical Center of HematologyXinqiao HospitalState Key Laboratory of TraumaBurn and Combined InjuryArmy Medical UniversityChongqing 400037China Department of HematologyTianjin First Central HospitalTianjin 300192China Department of HematologyShanghai Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Department of HematologyTongji Hospital of Tongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China
出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)
年 卷 期：2023年第20卷第2期
页 面：129-146页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by funds from the National Natural Science Foundation of China(Grant Nos.81830002,81830004,82070168,and 32070951) the Translational Research grant of NCRCH(Grant No.2020ZKZC04) National Key R&D Program of China(Grant No.2021YFA1100800)
主 题：CAR T-cell therapy B-cell non-Hodgkin lymphoma toxicity cytokine-release syndrome clinical management
摘 要：Adoptive cellular immunotherapy with chimeric antigen receptor(CAR)T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma(B-NHL).With increasing approval of CAR T-cell products and advances in CAR T cell therapy,CAR T cells are expected to be used in a growing number of ***,CAR T-cell-associated toxicities can be severe or even fatal,thus compromising the survival benefit from this *** and studying the clinical management of these toxicities are *** contrast to other hematological malignancies,such as acute lymphoblastic leukemia and multiple myeloma,anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features,most notably local cytokine-release syndrome(CRS).However,previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for ***,we developed this consensus for the prevention,recognition,and management of these toxicities,on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese *** consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management,and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.
维普期刊数据库
同方期刊数据库